Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody

12 Apr 2014

Abstract excerpt

Immunosuppression in the tumor microenvironment blunts vaccine-induced immune effectors. PD-1/B7-H1 is an important inhibitory axis in the tumor microenvironment. Our goal in this study was to determine the effect of blocking this inhibitory axis during and following vaccination against breast cancer. We observed that using anti-PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24728077
DOI: 10.1158/0008-5472.can-13-2564

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 AntibodyPMID 24728077Read ↗

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.Semantic proximity Read ↗

Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine.Semantic proximity Read ↗

CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.Semantic proximity Read ↗

Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.Semantic proximity Read ↗

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor ImmunitySemantic proximity Read ↗

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.Semantic proximity Read ↗

CD40 agonism enhances immune checkpoint blockade and generates immunologic memory via CD4+ T cells in ERα+ mammary tumorsSemantic proximity Read ↗

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.Semantic proximity Read ↗

Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.Semantic proximity Read ↗

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer modelSemantic proximity Read ↗

Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses <i>in vitro</i>Semantic proximity Read ↗

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.